European Commission grants marketing authorisation for aflibercept biosimilar Afqlir (Sandoz Group)

News
Article

The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration

A large vertical banner, indicating the headquarters of the European Commission, hanging on the southern wing of the Berlaymont building. Image credit: ©olrat – stock.adobe.com

The biosimilar is expected to launch as of Q4 2025. Image credit: ©olrat – stock.adobe.com

The European Commission (EC) granted marketing authorisation for Afqlir (aflibercept), which is a 2 mg vial kit and pre-filled syringe for intravitreal injection. Afqlir, produced by Sandoz Group, is a biosimilar to reference aflibercept, known by the brand name Eylea (Bayer AG). The biosimilar is indicated to treat retinal diseases, including neovascular age-related macular degeneration (nAMD), macular oedema following retinal vein occlusion, diabetic macular oedema and myopic choroidal neovascularisation, according to a press release about Afqlir from Sandoz Group.1

This approval is a notable milestone in the company’s growth.

Claire D’Abreu-Hayling, Chief Scientific Officer for Sandoz, is quoted in the press release discussing the news. She stated, "Vision loss significantly affects daily activities, from work to social interactions. Early and expanded access to effective treatments is essential for patients to maintain and improve their visual acuity. The approval of Afqlir is a pivotal moment in delivering an affordable and effective treatment option to patients in Europe who are affected by conditions such as nAMD. This milestone underscores our commitment to improving patient outcomes through accessible, high-quality biosimilars."

The biosimilar is expected to launch by Q4 2025.1

According to the company, the active ingredient in Afqlir is aflibercept, a recombinant fusion protein and anti-vascular endothelial growth factor A (VEGF-A) agent. "The robust biosimilar development program of Afqlir consisted of a comprehensive package including analytical and preclinical in vitro study data, as well as clinical data from the Mylight study," the press release detailed. These study findings confirmed that the biosimilar displays equivalent efficacy and comparable safety to its reference medicine.

Reference:

1. Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio. Sandoz Group. November 15, 2024. Accessed November 15, 2024. https://www.globenewswire.com/news-release/2024/11/15/2981760/0/en/Sandoz-receives-European-Commission-approval-for-Afqlir-aflibercept-further-strengthening-leading-biosimilar-portfolio.html

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.